Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization
Completed · Phase 4
Conditions studied: Chronic Kidney Disease, Acute Kidney Injury, Heart Disease
In brief
The investigators will conduct a randomized controlled trial that aims to compare the incidence of contrast-induced nephropathy between transradial- and transfemoral-access cardiac catheterization.
Key facts
- Study ID
- NCT02933892
- Run by
- Texas Tech University Health Sciences Center
- People needed
- 39
- Starts
- 2016-10-01
- Expected to finish
- 2024-08-30
- Last updated by the study team
- 2024-11-06
Who can join
Age: 18 and older, up to 88. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients scheduled to undergo non-emergent cardiac catheterization at University Medical Center Hospital, Lubbock, TX from January 2016 to January 2018. Emergent cardiac catheterizations will be defined as a catheterization scheduled < 24 hours from a cardiac event.
- Patients willing to be randomized to TFA or TRA procedure.
- Patients signed and dated the informed consent agreeing to participate in the study.
- Patients with chronic kidney disease, defined as eGFR = 15-59mL/min defined by the MDRD formula. (eGFR is a standard of care measurement for all patients undergoing coronary intervention.).
- Patients ages 18-88 years old.
You may not qualify if…
- Patients who have previously undergone a coronary artery bypass graft procedure.
- Patients with prior catheterization within the last 5 years.
- Women who are pregnant or expect to become pregnant. Pregnancy tests for women of childbearing potential (WOCHP) will be performed as standard of care.
- Patients with a history of cardiogenic shock.
- Children (under the age of 18).
- Medical, geographical, or social factors making study participation impractical, i.e. documented noncompliance, unable to return for follow-ups and lab draws, etc.
- A positive Allen's Test on the right radial artery.
- Any condition preventing TRA or TFA access.
- Contrast used within the previous 3 weeks.
- Allergy to contrast dye.
- Inability to successfully access the artery randomized to use.
Where it is running
- Texas Tech University Health Sciences Center — Lubbock, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.